Head-to-head evidence
APNmAb005 vs Bepranemab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Tau (monoclonal antibody) · full Alzheimer's Disease pipeline
APNmAb005
Developed by APRINOIA Therapeutics
NCT05344989 · Phase 1 · status unknown
This is a randomized, placebo-controlled study with full blinding of participants, care providers, and assessors, though it is an early, safety-focused, first-in-human study in healthy volunteers rather than a disease-population efficacy trial, with small dose-cohort sizes. Results have not yet been posted.
Bepranemab
Developed by UCB
NCT04867616 · Phase 2 · completed
The study randomized 466 participants to two bepranemab dose groups or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical endpoint was change in CDR-SB at Week 80, but whether this endpoint was met cannot be determined because results are not posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: APNmAb005's landscape · Bepranemab's landscape